Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

UBT251

UBT251 Injection Phase II Study (Overweight or Obesity)

The United Bio-Technology (Hengqin) Co · Phase 2 · Completed · Enrollment 205

NCT07177469

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
UBT251 Injection 2.0 mgn/rn/rn/rn/r
UBT251 Injection 4.0 mg(ID 0.5 mg)n/rn/rn/rn/r
UBT251 Injection 4.0 mg(ID 1.0 mg)n/rn/rn/rn/r
UBT251 Injection 6.0 mgn/rn/rn/rn/r

Not shown

  • UBT251 Injection 2.0 mg: endpoint not reported
  • UBT251 Injection 4.0 mg(ID 0.5 mg): endpoint not reported
  • UBT251 Injection 4.0 mg(ID 1.0 mg): endpoint not reported
  • UBT251 Injection 6.0 mg: endpoint not reported